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INTRODUCTION
Fibroblast growth factor 21 (FGF21) is a member
of the FGF subfamily and was originally isolated
from the liver (1). FGF21 is a member of the diverse
“hormone-like” subgroup within the FGF subfam-
ily that also includes FGF19 and FGF23 (2). Hor-
mone-like FGF signaling disorders caused by he-
reditary diseases or tumors are associated with meta-
bolic disease (3). In addition, serum hormone-like
ORIGINAL
Correlation of fibroblast growth factor 21 serum levels
with metabolic parameters in Japanese subjects
Qing-Ri Jin1, Yukiko Bando2, Katsuyuki Miyawaki1, Yosuke Shikama2,
Chisato Kosugi2, Nanako Aki2,3, Makoto Funaki2, and Sumihare Noji4*
1Department of Life Systems, Institute of Technology and Science, the University of Tokushima, 2-1
Minami-jyousanjima-cho, Tokushima City, Japan 770-8506., 2Clinical Research Center for Diabetes,
Tokushima University Hospital, Tokushima, Japan, 3Department of Medicine and Bioregulatory Sci-
ences, Institute of Health Biosciences, the University of Tokushima Graduate School, Tokushima, Japan,
4Diabetes Therapeutics and Research Center, the University of Tokushima, Tokushima, Japan
Abstract : Objects : Since serum level of fibroblast growth factor 21 (FGF21) has been im-
plicated as a potential biomarker for the early detection of the metabolic syndrome and
type 2 diabetes, we examined how FGF21 serum levels are correlated with metabolic pa-
rameters in Japanese subjects. Methods : FGF21 levels were analyzed by enzyme-linked
immunosorbent assays. Spearman’s correlation and multiple stepwise regression analyses
were used to examine the relationship between serum FGF21 and other factors. A Mann-
Whitney U test was performed between the normal and high groups for triglycerides and
systolic blood pressure (BP) respectively. Results : By univariate correlation analysis, se-
rum FGF21 levels were significantly associated with triglyceride levels, systolic BP, dia-
stolic BP, pulse pressure, body mass index (BMI), age, fasting plasma glucose (FPG) levels,
and total cholesterol levels. Multiple regression analysis (adjusted for age, gender, and
BMI) showed that serum FGF21 levels were independently and significantly associated
with triglyceride levels and systolic BP. Serum FGF21 levels were significantly higher
in subjects with high triglyceride levels and high systolic BP compared with those who
had normal triglyceride levels and normal systolic BP respectively. Conclusions : This
study found that FGF21 levels might be a biomarker for somemetabolic disorders asso-
ciated with metabolic syndrome. J. Med. Invest. 61 : 28-34, February, 2014
Keywords : FGF21, metabolic syndrome, triglycerides, systolic BP, biomarker
Abbreviations : FGF21, fibroblast growth factor 21 ; BP, blood
pressure ; BMI, body mass index ; FPG, fasting plasma glucose ;
NAFLD, nonalcoholic fatty liver disease ; HDL, high-density lipo-
protein ; HbA1c, hemoglobin A1c ; LDL, low-density lipoprotein ;
S.D., standard deviation.
Received for publication July 26, 2013 ; accepted August 26, 2013.
*Address correspondence and reprint requests to Sumihare Noji,
the University of Tokushima, Shinkura-cho, Tokushima City,
Japan, 770-8501 and Fax : +81-88-656-9301.
The Journal of Medical Investigation Vol. 61 2014
28
FGF levels are significantly affected in some meta-
bolic disorders (3). Serum FGF19 levels are sig-
nificantly increased in patients on chronic hemo-
dialysis (4) and significantly decreased in nonal-
coholic fatty liver disease (NAFLD) patients (5).
Serum FGF23 levels are also greatly increased in
patients with renal failure (6, 7). Numerous recent
studies have focused on FGF21 as a key regulator
or biomarker. Li et al. reported that FGF21 levels
are increased in NAFLD patients and suggested
that serum FGF21 could be potentially used as a
biomarker for NAFLD (8). Serum FGF21 levels are
also increased in patients with type 2 diabetes, obe-
sity (9-11) and Cushing’s syndrome (12). In con-
trast, serum FGF21 levels are decreased in patients
with anorexia nervosa (13) and in patients with type
1 diabetes (14). Eto et al. reported that the serum
concentration of FGF21 is associated with clinical
parameters in Japanese patients with type 2 diabetes
(15). In addition, FGF21 has been shown to be an
independent predictor of type 2 diabetes (16). Taken
together, these results suggest that FGF21 could
be a biomarker for metabolic disorders such as type
2 diabetes. Further understanding of the functions
of hormone-like FGFs will provide clues to their
roles in metabolism and clinical treatments for meta-
bolic diseases (3).
According to the International Diabetes Federa-
tion (17) metabolic syndrome is defined as central
obesity and any two of the following : (1) high tri-
glycerides defined as150 mg/dL (1.7 mmol/L),
or specific treatment for this lipid abnormality ; (2)
reduced high-density lipoprotein (HDL) cholesterol
defined as 40 mg/dL (1.03 mmol/L) in men or
50 mg/dL (1.29 mmol/L) in women, or specific
treatment for this lipid abnormality ; (3) high BP
of systolic BP130 or diastolic BP85 mmHg, or
treatment of previously diagnosed hypertension ; (4)
high FPG defined as100 mg/dL (5.6 mmol/L), or
previously diagnosed type 2 diabetes (17). This in-
dicates that metabolic syndrome is strongly asso-
ciated with obesity, triglycerides, HDL cholesterol,
BP, and FPG.
Tokushima Prefecture, Japan, has a high rate of
obesity : 37% of men are obese (18, 19). To prevent
an onset of metabolic syndrome in Tokushima, suit-
able biomarkers must be found that are associated
with the clinical parameters affected in metabolic
syndrome, since these biomarkers might predict
an onset of metabolic syndrome. However, no stud-
ies to date have reported a correlation between
FGF21 levels and clinical parameters associated with
metabolic syndrome in Japan, including Tokushima.
This study is a first report concerning serum FGF21
levels and metabolic disorders in Japanese subjects.
In this study, we measured the serum concentration
of FGF21 in 998 Japanese subjects in Tokushima
Prefecture and investigated its relationship with clini-
cal parameters. We found that serum FGF21 levels
correlated with some clinical parameters used in
diagnosing metabolic syndrome. In addition, we
showed that people with either high triglycerides or
systolic BP exhibit higher levels of serum FGF21
than people with normal triglycerides levels or sys-
tolic BP.
MATERIALS AND METHODS
Recruitment and eligibility
A total of 1068 participants aged 20 to 65 years
old participated in a cross-sectional study conducted
by the Clinical Research Center for Diabetes at the
Tokushima University Hospital. This study was ap-
proved by the Ethics Committees of the Tokushima
University Hospital. Further inclusion criteria were
the absence of any other disorder or medication
known to affect the serum FGF21 level. All patients
gave informed consent to participate in the study.
To evaluate clinical parameters accurately, 70 par-
ticipants were excluded because they were either
receiving medication for metabolic disorders such
as diabetes, dyslipidemia and hypertension, or were
not fasting at the time of blood examination. The
remaining 998 subjects (752 men and 246 women)
were analyzed in this study.
Anthropometric and biochemical measurements
Height (cm) and weight (kg) were measured.
BMI was calculated as weight in kilograms divided
by the square of height in meters. Systolic BP and
diastolic BP were measured by standard methods.
Blood samples were drawn after overnight fasting
by venipuncture to measure levels of serum glucose,
hemoglobin A1c (HbA1c), triglyceride, total cho-
lesterol, HDL cholesterol, and low-density lipopro-
tein (LDL) cholesterol. These factors were meas-
ured by standard enzymatic methods. FGF21 levels
were analyzed by enzyme-linked immunosorbent
assays (BioVendor, Modrice, Czech Republic) ac-
cording to the manufacturer’s instructions. Intra-
and inter-assay precision of ELISA were 3.4% and
6.1% respectively. HbA1c levels were analyzed by a
high-performance liquid chromatography assay and
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expressed by NGSP values.
Definition of normal and high groups
Subjects were divided into two groups by either
triglyceride levels or systolic BP. Subjects with tri-
glyceride levels lower than 150 mg/dL were in the
normal group (18149 mg/dl, n=814). Those with
triglyceride levels equal to or higher than 150 mg/dl
were in the high group (1502819 mg/dl, n=184).
Subjects with systolic BP lower than 130 mmHg
were in the normal group (82129 mmHg, n=798),
and those with systolic BP equal to or higher than
130 mmHg were included in the high group (130
202 mmHg, n=200) (20).
Statistical analysis
Statistical analyses were performed using SPSS
19.0 software (SPSS ; Chicago, IL, USA). Because
serum FGF21 levels were not normally distributed,
they were logarithmically converted and used for
correlation analysis and multiple stepwise regression
analysis. Spearman’s correlation and multiple step-
wise regression analyses were used to examine the
relationship between serum FGF21 and other fac-
tors. Factors that were significantly correlated to
serum FGF21 were selected for multiple stepwise
regression analysis. A Mann-Whitney U test was
performed between the normal and high groups
for triglycerides and systolic BP, respectively. All
data were presented as meanstandard deviation
(S.D). In all statistical analyses, a p value less than
0.05 was considered statistically significant.
RESULTS
In this study, 998 subjects were analyzed (men/
women=752/246). Clinical parameters of study
subjects are in Table 1. The distribution of serum
FGF21 concentrations was broad (16-4577 pg/ml,
median value 189 pg/ml), and the meanS.D value
was 272388 pg/ml. No significant difference was
seen in serum FGF21 levels between men and
women (280405 pg/ml vs. 248329 pg/ml, p=
0.917).
Using univariate correlation analysis, serum
FGF21 levels were most significantly associated with
triglyceride levels (r=0.200, p0.001, Figure 1). The
second most significant association was observed
between serum FGF21 and systolic BP (r=0.167, p
0.001, Figure 2). Serum FGF21 levels were also as-
sociated with diastolic BP (r=0.145, p0.001), BMI
(r=0.114, p0.001), age (r=0.105, p=0.001), FPG
(r=0.093, p=0.003), pulse pressure (r=0.086, p=
0.006) and total cholesterol (r=0.066, p=0.036) lev-
els, although correlation coefficients were low (Table
2). No significant correlation was seen between
FGF21 levels and gender, HbA1c, LDL cholesterol,
or HDL cholesterol levels (Table 2).
We conducted multiple regression analysis adjust-
ing for age, gender, and BMI. Serum FGF21 levels
were independently and significantly associated with
triglyceride levels and systolic BP (Table 3).
Table 1. Clinical parameters of study subjects
Parameter Value
n 998
Age (years) 4110
BMI (kg/m2) 23.43.4
Systolic BP (mmHg) 12015
Diastolic BP (mmHg) 7511
Pulse pressure (mmHg) 458.3
Triglyceride (mg/dl) 10776
Total cholesterol (mg/dl) 19832
LDL cholesterol (mg/dl) 12030
HDL cholesterol (mg/dl) 5715
FPG (mg/dl) 919
HbA1c (%) 5.130.34
FGF21 (pg/ml) 272388
Data are expressed as meanS.D.
Abbreviations : BMI, body mass index ; BP, blood pressure ;
LDL, low-density lipoprotein ; HDL, high-density lipoprotein ;
FPG, fasting plasma glucose ; HbA1c, hemoglobin A1c ; FGF21,
fibroblast growth factor 21.
Figure 1. Correlation between log serum FGF21 levels and
triglyceride levels. Log serum FGF21 concentrations were plotted
against triglyceride concentrations. Line indicates the calculated
linear correlation curve.
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Finally, we performed Mann-Whitney U tests to
determine if serum FGF21 was elevated in people
with higher levels of either triglycerides or systolic
BP. As shown in Figures 3 and 4, the serum levels
of FGF21 were significantly higher in subjects with
high triglyceride levels or high systolic BP than in
those with triglyceride or systolic BP values in the
normal range.
DISCUSSION
In this study we analyzed clinical parameters as-
sociated with serum FGF21 levels in subjects re-
cruited in Tokushima, Japan, who were not under
medication for metabolic disorders. Our results
showed that serum FGF21 levels were independ-
ently and significantly associated with triglyceride
levels and systolic BP. These results were consistent
with a previous study of type 2 diabetes patients
Figure 2. Correlation between log serum FGF21 levels and
systolic BP. Log serum FGF21 concentrations were plotted
against systolic BP. Line indicates the calculated linear corre-
lation curve.
Table 2. Factors associated with serum FGF21 levels
Factor FGF21 (n=998)
r p
Age 0.105 0.001
Gender -0.034 0.285
BMI 0.114 0.001
Systolic BP 0.167 0.001
Diastolic BP 0.145 0.001
Pulse pressure 0.086 0.006
Triglyceride 0.200 0.001
Total cholesterol 0.066 0.036
LDL cholesterol 0.046 0.150
HDL cholesterol -0.052 0.100
FPG 0.093 0.003
HbA1c 0.05 0.116
Spearman’s correlation analysis was used to examine an asso-
ciation between serum FGF21 and other factors. r is a correla-
tion coefficient and a p value less than 0.05 was considered sta-
tistically significant.
Abbreviations : BMI, body mass index ; BP, blood pressure ;
LDL, low-density lipoprotein ; HDL, high-density lipoprotein ;
FPG, fasting plasma glucose ; HbA1c, hemoglobin A1c.
Table 3. Multiple stepwise regression analysis adjusted for
age, gender, and BMI
Factor FGF21 (n=998)
β p
Triglyceride 0.140 0.001
Systolic BP 0.112 0.001
Factors significantly associated with serum FGF21 were se-
lected for multiple stepwise regression analysis. β is a standard-
ized coefficient and a p value less than 0.05 was considered sta-
tistically significant.
Abbreviations : BMI, body mass index ; BP, blood pressure.
Figure 3. Serum FGF21 concentration in subjects with normal
triglycerides levels (n=814) and subjects with high triglycerides
levels (n=184).
Figure 4. Serum FGF21 concentration in subjects with normal
systolic BP (n=798) and subjects with high systolic BP (n=200).
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(15), which verifies the reliability and validity of our
study design and data. We compared for the first
time serum levels of FGF21 between two groups :
those with either high triglyceride levels or high
systolic BP and those with either of these parame-
ters in the normal range, by applying cut-off values
used to diagnose metabolic syndrome (17).
As shown in Figures 3 and 4, serum FGF21 lev-
els were significantly elevated in people with higher
triglyceride levels or higher systolic BP. Because
these factors are associated with metabolic syn-
drome, these results suggested that serum FGF21
level could be a promising biomarker for metabolic
disorders associated with metabolic syndrome. A
prospective cohort study will be necessary to estab-
lish the significance of FGF21 as a biomarker for
metabolic disorders associated with metabolic syn-
drome and metabolic syndrome itself.
The serum level of FGF21 was independently and
significantly associated with systolic BP (Table 2).
Furthermore, subjects with high systolic BP exhib-
ited a significantly higher level of FGF21 (Figure
4). Hypertension has been known to increase the
risk of cardiovascular disease (21). High levels of
triglycerides in the bloodstream, which exhibited
an association with high FGF21 level (Figure 1 and
3), has been also linked to atherosclerosis (22),
which, in turn, increases the risk of heart disease
and stroke. In fact, Lin and colleagues have reported
that increased serum FGF21 level is associated with
coronary heart disease, which is independent of
adverse lipid profile (23). In addition, our data re-
vealed that FGF21 levels were significantly associ-
ated with pulse pressure that has been known to
be a cardiovascular risk factor independent of sys-
tolic blood pressure (24). Hence, FGF21 might serve
as a biomarker for the risk of cardiovascular dis-
eases. Further research is necessary to test this
possibility.
Previous reports demonstrated that serum triglyc-
eride levels and hepatic triglyceride contents are
reduced by FGF21 administration (25, 26). Thus,
as suggested previously (10), the positive associa-
tion between FGF21 levels and triglyceride levels
found in this study might indicate a state of “FGF21
resistance”, in which FGF21 fails to maintain triglyc-
eride levels within the normal range. Triglycerides,
as one of the major components of very low-density
lipoprotein and chylomicrons, are important in lipid
metabolism as an energy source and transporters
for dietary fat. We found that FGF21 levels were
significantly increased in subjects with triglyceride
levels equal to or higher than 150 mg/dl (Figure 3).
Thus, our results suggest that serum FGF21 level
could be a biomarker for abnormal lipid metabolism
by reporting the degree of FGF21 resistance.
Fibrates, antihyperlipidemic agents and agonists
for the transcription factor peroxisome proliferator-
activated receptor (PPAR)-α, are known to upregu-
late the expression and serum concentration of
FGF21 (27). Furthermore, Dutchak and colleagues
had reported the existence of PPARγ -response ele-
ments in the upstream region of the FGF21 gene
to enhance its expression, the authors found that
the FGF21 knockout in mice showed defects in
PPARγ signaling (28). Therefore, we can postulate
that FGF21, as a crucial mediator of PPARγ signal
transduction, has a connection with development of
hypertension at least in part via retention of fluid
(27). However we still didn’t know the association
between neuronal system controlling blood pressure
and FGF21 signaling.
Limitations of our study were that the study de-
sign was cross-sectional with potential selection bias.
In addition, our results had low correlation coeffi-
cients.
In conclusion, FGF21 levels are associated with
serum triglyceride levels and systolic BP. Further
cohort studies could determine the usefulness of
serum FGF21 levels as a biomarker for some meta-
bolic disorders associated with metabolic syndrome.
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